EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
Watching ESSA Pharma Shares Following Circulation Of Zack’s Small Cap Research Note Showing $45 Valuation Target
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_05272022_EPIX_Bautz.pdf
EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
ESSA Pharma Q2 EPS $0.66 Up From $(0.36) YoY
ESSA Pharma (NASDAQ:EPIX) reported quarterly earnings of $0.66 per share. This is a 283.33 percent increase over losses of $(0.36) per share from the same period last year.
